Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world, and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan's team to expedite the trials for the drug, as there is significant market demand for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest taking shortcuts to expedite the clinical trials and obtain requisite approvals. These include manipulating data to exclude negative outcomes, selectively reporting positive results, foregoing the process of informed consent, and using compounds already patented by a rival company, rather than developing one's own component. Dr. Srinivasan is not comfortable taking such shortcuts, but at the same time, he realises that meeting the targets is impossible without using these means. (a) What would you do in such a situation? (b) Examine your options and consequences in light of the ethical questions involved. (c) How can data ethics and drug ethics save humanity at large in such a scenario?

Speeding up a drug for a pandemic is a legitimate goal, but not through falsified data, skipped consent or stolen intellectual property. I would refuse all four shortcuts and pursue faster, lawful routes.

(a) My course of action

• Put my refusal in writing and inform the CEO, the chief medical officer and the legal team.
• Ask the Institutional Ethics Committee (IRB) to review the trial plan and the proposed changes.
• Propose a phased, adaptive trial design with interim analyses and rolling review by the regulator under the New Drugs and Clinical Trials Rules, 2019.
• If coercion continues, report to CDSCO and the Drugs Controller General of India, and use whistleblower protection.

(b) Options and consequences

• Complying with the shortcuts violates the Declaration of Helsinki and ICH-GCP. Consent given on manipulated data is not informed consent, so patient autonomy is breached.
• Selective reporting causes utilitarian harm: an unsafe drug reaching millions and a later recall that destroys public trust. Drugs and Cosmetics Act, 1940 liability and IPC 304A exposure follow.
• Using the rival's patented compound infringes the Patents Act, 1970, inviting injunctions that halt launch and defeat the speed goal. Compulsory licensing under Section 84 during a health emergency, or a licence from the rival, is the lawful route.
• Deontologically, the duty to patients and to scientific integrity outweighs market pressure. Stakeholders include patients, shareholders, the scientific community and the regulator.

(c) Data and drug ethics for humanity

• Transparent reporting of all trial results, with independent data audits and public trial registration on CTRI, prevents hidden harms. The Thalidomide disaster showed the cost of skipping proper trials.
• Informed consent, privacy and equitable access protect vulnerable groups from exploitation and support global health equity.
• Regulators, ethics committees and international standards such as WHO and ICH-GCP give enforcement teeth. COVID-19 vaccine data sharing showed that transparency builds global trust.

Thus, ethical data and drug practices are not obstacles to speed. They are the only sustainable route to a safe drug that the public will accept.